ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
IPO Year:
Exchange: NYSE
Website: resmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2025 | $280.00 | Overweight | Morgan Stanley |
| 3/19/2025 | Overweight | Morgan Stanley | |
| 1/16/2025 | Buy | Goldman | |
| 1/10/2025 | $252.00 | Neutral | Piper Sandler |
| 12/13/2024 | $250.00 | Hold | Stifel |
| 9/24/2024 | $280.00 | Outperform | Robert W. Baird |
| 9/18/2024 | $180.00 | Peer Perform → Underperform | Wolfe Research |
| 9/4/2024 | Buy → Hold | Needham | |
| 6/25/2024 | Outperform → Perform | Oppenheimer | |
| 6/24/2024 | Buy → Neutral | Citigroup |
144 - RESMED INC (0000943819) (Subject)
8-K - RESMED INC (0000943819) (Filer)
144 - RESMED INC (0000943819) (Subject)
8-K - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
10-Q - RESMED INC (0000943819) (Filer)
8-K - RESMED INC (0000943819) (Filer)
DEFA14A - RESMED INC (0000943819) (Filer)
DEF 14A - RESMED INC (0000943819) (Filer)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
SC 13G/A - RESMED INC (0000943819) (Subject)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
4 - RESMED INC (0000943819) (Issuer)
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa
Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual's home. OSA, a sleep disorder where breathing repeatedly stops during sleep due to blocked upper airways, affects nearly one billion people globally1, yet approximately 80% of cases remain undiagnosed and untreat
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Wednesday, April 23, 2025, 9:30 p.m. BST Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST Please note,
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life. OSA affects over one billion people worldwide,1 with over 80% of cases undiagnosed and untreated.2 This chron
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company's last major brand update in 2014 marked its shift to connectivity, introducing cloud-connected medical devices that revolutionized sleep apnea therapy. Today, Resmed is taking the next step –
7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)), a global health technology leader focused on sleep, breathing, and care delivered in the home, today unveiled the findings of its fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscores a widespread global sleep crisis, with people losing an average of nearly three nights of restorative sleep
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's
DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the worldBoard appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board au
Rider and Haake, both internal promotions, joined ResMed's executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed's first Chief Quality Officer, effective May 1, 2023. Both joined ResMed's executive team on May 1 and report to the Office of the CEO. Michael Rider was selected following a previously a
SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced ResMed's board of directors has appointed chief executive officer Michael ("Mick") Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member. Mick Farrell became ResMed's CEO on March 1, 2013, and has served as a member of the company's board of directors since assuming that role. "I am honored to expand my role with ResMed as its next chair and to succeed my dad, Peter Farrell, whose vision, leadership, and guidance have helped ResMed become the largest outside-hospital, digital
Tyagi brings over 25 years' IT and leadership experience from ADP, American Express, Amazon, Microsoft, and IBMCurrent CTO and SaaS President Bobby Ghoshal now transitions to SaaS full-time SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced the appointment of Urvashi Tyagi as chief technology officer (CTO), effective today. As CTO, Tyagi will lead ResMed's Digital Health Technology team, driving the innovation and adoption of its world-leading cloud-based digital health platforms, as well as investments in emerging technologies like artificial intelligence and machine learning. Tyagi has over 25 years' experience in IT and mechanical enginee
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has appointed Jan D. De Witte as its next President and Chief Executive Officer. Mr. De Witte succeeds Peter J. Arduini, who previously announced he will step down as Chief Executive Officer to accept the role of President and Chief Executive Officer of GE Healthcare. Mr. De Witte will join Integra prior to the end of the year, at which time he will also be appointed to Integra's board of directors. With over two decades in the healthcare industry, De Witte brings global public company leadership experience as well
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelectronic medicine company. Named one of Women Inc. magazine’s most influential corporate directors in 2018, Drexler brings to Outset a deep understanding of how to utilize data analytics and mac
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa
Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 140 bps to 59.3%; non-GAAP gross margin improved 140 bps to 59.9%Income from operations increased 14%; non-GAAP income from operations up 13
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:https://investor.resmed.com •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Wednesday, April 23, 2025, 9:30 p.m. BST Sydney, Thursday, April 24, 2025, 6:30 a.m. AEST Please note,
Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2024. Second Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%Income from operations increased 52%; non-GAAP income from operations
SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:https://investor.resmed.com• Date:Thursday, January 30, 2025• Time:1:30 p.m. PST / 4:30 p.m. EST• International:London, Thursday, January 30, 2025, 9:30 p.m. GMT Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT Please no
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended September 30, 2024. First Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 11% to $1.2 billion; up 11% on a constant currency basis Gross margin improved 420 bps to 58.6%; non-GAAP gross margin improved 320 bps to 59.2%Income from operations increased 34%; non-GAAP income from operation
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, October 24, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, October 24, 2024, 9:30 p.m. BSTSydney, Friday, October 25, 2024, 7:30 a.m.
Year-over-year revenue grows 9%, operating profit up 38%, non-GAAP operating profit up 30%Operating cash flow of $440 millionQuarterly dividend increases 10% to $0.53 per shareCompany to host an Investor Day on September 30, 2024 Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis Gross margin improved 350 bps to 58.5%; non-GAAP gross ma
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE:RMD, ASX: RMD))) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: http://investor.resmed.com Date: Thursday, August 1, 2024 Time: 1:30 p.m. PDT / 4:30 p.m. EDT International: London, Thursday, August 1,
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE:RMD, ASX: RMD))) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency basis Gross margin grew 260 bps to 57.9%; non-GAAP gross margin grew 240 bps to 58.5%Income from operations increased 25%; non-GAAP operating profit u
Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00
Morgan Stanley initiated coverage of ResMed with a rating of Overweight
Goldman initiated coverage of ResMed with a rating of Buy
Piper Sandler initiated coverage of ResMed with a rating of Neutral and set a new price target of $252.00
Stifel initiated coverage of ResMed with a rating of Hold and set a new price target of $250.00
Robert W. Baird initiated coverage of ResMed with a rating of Outperform and set a new price target of $280.00
Wolfe Research downgraded ResMed from Peer Perform to Underperform and set a new price target of $180.00
Needham downgraded ResMed from Buy to Hold
Oppenheimer downgraded ResMed from Outperform to Perform
Citigroup downgraded ResMed from Buy to Neutral